

Polar Capital Global Healthcare Growth And Income Trust
Sector Exposure Summary
As at 28 April 2017

Sectors	%	£ ('000s)
Biotechnology	6.04%	15,032
Abbvie	1.64%	4,076
Celgene	1.16%	2,877
Alexion	1.07%	2,654
Incyte	0.96%	2,402
Newron	0.69%	1,707
Summit	0.53%	1,318
Healthcare Distributors	0.16%	397
Sigma	0.16%	397
Healthcare Equipment	9.48%	23,606
Abbott	2.71%	6,746
Medtronic	2.06%	5,137
Consort	1.97%	4,897
Spectranetics	0.98%	2,427
Abiomed	0.73%	1,813
Oxford Immunotec	0.58%	1,433
Novadaq	0.32%	806
Inogen	0.14%	347
Healthcare Facilities	3.41%	8,483
HCA	1.05%	2,603
Virtus	0.60%	1,485
Sienna Senior Living	0.58%	1,452
Medical Facilities	0.55%	1,378
Extencare	0.28%	705
Brookdale Senior Living	0.24%	602
Circle Holdings	0.10%	258
Healthcare REITs	5.70%	14,181
HCP	0.97%	2,423
Medical Properties Trust	0.89%	2,223
RHT Health Trust	0.73%	1,819
Senior Housing Property Trust	0.67%	1,663
Sabra Healthcare	0.63%	1,576
Healthcare Reality Trust	0.61%	1,521
National Health Investors	0.57%	1,414
Omega Healthcare Investors	0.51%	1,275
Quality Care Properties	0.11%	268
Healthcare Services	4.32%	10,755
Sonic Healthcare	1.18%	2,929
UDG Healthcare	0.90%	2,238
Laboratory Corp	0.87%	2,167
Fresenius Medical Care	0.55%	1,373
Healthcare Services Group	0.55%	1,361
Primary Health Care	0.28%	688

Healthcare Supplies	1.55%	3,857
Quotient	0.69%	1,706
Coltene	0.66%	1,643
Meridian	0.20%	509
Life & Health Insurance	0.69%	1,716
NIB	0.69%	1,716
Life Sciences Tools & Services	0.61%	1,506
Perkinelmer	0.58%	1,446
Epistem	0.02%	60
Managed Healthcare	3.39%	8,429
Unitedhealth	1.36%	3,379
Anthem	1.10%	2,750
Centene	0.92%	2,300
Pharmaceuticals	59.17%	147,280
Pfizer	7.37%	18,342
Merck & Co	7.16%	17,823
Johnson & Johnson	6.14%	15,271
Sanofi	5.42%	13,485
GlaxoSmithKline	4.83%	12,013
Novartis	4.53%	11,286
Merck	4.38%	10,893
Roche	4.06%	10,102
Astellas	3.48%	8,652
Bristol Myers Squibb	3.31%	8,232
Takeda	2.23%	5,553
Eli Lilly	1.91%	4,757
AstraZeneca	1.68%	4,172
Lundbeck	0.90%	2,245
Revance	0.62%	1,551
Jazz Pharmaceuticals	0.59%	1,477
Photocure	0.34%	848
Oxford Pharmascience	0.23%	578
Cash	5.48%	13,647
Total	94.52%	235,242

Important Information: This document is provided for the sole use of the intended recipient and is not a financial promotion it shall not and does not constitute an offer or solicitation of an offer to make an investment into any fund or Company managed by Polar Capital. It may not be reproduced in any form without the express permission of Polar Capital and is not intended for private investors. This document is only made available to professional clients and eligible counterparties. The law restricts distribution of this document in certain jurisdictions; therefore, it is the responsibility of the reader to inform themselves about and observe any such restrictions. It is the responsibility of any person/s in possession of this document to inform themselves of, and to observe, all applicable laws and regulations of any relevant jurisdiction. Polar Capital Global Healthcare Growth and Income Trust plc is an investment company with investment trust status and as such its ordinary shares are excluded from the FCA's (Financial Conduct Authority's) restrictions which apply to non-mainstream investment products. The Company conducts its affairs and intends to continue to do so for the foreseeable future so that the exclusion continues to apply. It is not designed to contain information material to an investor's decision to invest in Polar Capital Global Healthcare Growth and Income Trust plc, an Alternative Investment Fund under the Alternative Investment Fund Managers Directive 2011/61/EU ("AIFMD") managed by Polar Capital LLP the appointed Alternative Investment Manager. In relation to each member state of the EEA (each a "Member State") which has implemented the AIFMD, this document may only be distributed and shares may only be offered or placed in a Member State to the extent that (1) the fund is permitted to be marketed to professional investors in the relevant Member State in accordance with AIFMD; or (2) this document may otherwise be lawfully distributed and the shares may otherwise be lawfully offered or placed in that Member State (including at the initiative of the investor). As at the date of this document, the Fund has not been approved, notified or registered in accordance with the AIFMD for marketing to professional investors in any member state of the EEA. However, such approval may be sought or such notification or registration may be made in the future. Therefore this document is only transmitted to an investor in an EEA Member State at such investor's own initiative. SUCH INFORMATION, INCLUDING RELEVANT RISK FACTORS, IS CONTAINED IN THE COMPANY'S OFFER DOCUMENT WHICH MUST BE READ BY ANY PROSPECTIVE INVESTOR.

Holdings: Portfolio data is "as at" the date indicated and should not be relied upon as a complete or current listing of the holdings (or top holdings) of the Company. The holdings may represent only a small percentage of the aggregate portfolio holdings, are subject to change without notice, and may not represent current or future portfolio composition. Information on particular holdings may be withheld if it is in the Company's best interest to do so. It should not be assumed that recommendations made in future will be profitable or will equal performance of the securities in this document. A list of all recommendations made within the immediately preceding 12 months is available upon request. This document is not a recommendation to purchase or sell any particular security. It is designed to provide updated information to professional investors to enable them to monitor the Company.

Regulatory Status: Polar Capital LLP is a limited liability partnership number OC314700. It is authorised and regulated by the UK Financial Conduct Authority ("FCA") and is registered as an investment adviser with the US Securities & Exchange Commission ("SEC"). A list of members is open to inspection at the registered office, 16 Palace Street, London, SW1E 5JD. FCA authorised and regulated investment managers are expected to write to investors in funds they manage with details of any side letters they have entered into. The FCA considers a side letter to be an arrangement known to the investment manager which can reasonably be expected to provide one investor with more materially favourable rights, than those afforded to other investors. These rights may, for example, include enhanced redemption rights, capacity commitments or the provision of portfolio transparency information which are not generally available. The Fund and the Investment Manager are not aware of, or party to, any such arrangement whereby an investor has any preferential redemption rights. However, in exceptional circumstances, such as where an investor seeds a new fund or expresses a wish to invest in the Fund over time, certain investors have been or may be provided with portfolio transparency information and/or capacity commitments which are not generally available. Investors who have any questions concerning side letters or related arrangements should contact the Polar Capital Desk at the Administrator on 0800 876 6889. The Fund is prepared to instruct the custodian of the Fund, upon request, to make available to investors portfolio custody position balance reports monthly in arrears.

Information Subject to Change: The information contained herein is subject to change, without notice, at the discretion of Polar Capital and Polar Capital does not undertake to revise or update this information in any way.

Performance/Investment Process/Risk: Factors affecting the Company's performance may include changes in market conditions (including currency risk) and interest rates and in response to other economic, political, or financial developments. The Company's investment policy allows for it to enter into derivatives contracts. Leverage may be generated through the use of such financial instruments and investors must be aware that the use of derivatives may expose the Company to greater risks, including, but not limited to, unanticipated market developments and risks of illiquidity, and is not suitable for all investors. Those in possession of this document must read the Company's Investment Policy and Annual Report for further information on the use of derivatives. Past performance is not a guide to or indicative of future results. Future returns are not guaranteed and a loss of principal may occur. Investments are not insured by the FDIC (or any other state or federal agency), or guaranteed by any bank, and may lose value. No investment process or strategy is free of risk and there is no guarantee that the investment process or strategy described herein will be profitable.